Analysts’ Viewpoint on Market Scenario
A large patient population is suffering from moderate to severe psoriatic arthritis, and the number is increasing across the globe. This presents significant opportunities to manufacturers in the global market. The global psoriatic arthritis therapeutics market is driven by extensive research to provide treatments and to relieve the symptoms of the condition.
Leading pharmaceutical companies are striving to address the unmet medical needs of severe psoriatic arthritis patients through new product development. Large number of small molecules and biologic products are under different phases of clinical trial for the treatment of psoriatic arthritis. Companies have made significant investments in clinical R&D and have established strategic partnerships and collaborations to accelerate new product development.
Psoriatic arthritis is a type of seronegative spondyloarthritis that is distinguished by inflammatory arthritis in conjunction with psoriasis. Psoriatic arthritis has a wide range of clinical manifestations, but the axial joints and distal interphalangeal joints are frequently involved. Interleukin inhibitors drugs have proven to be effective and well-tolerated treatment for psoriatic arthritis, and recently, around three different interleukin inhibitors have been approved and commercialized in the U.S. and Europe. Several different drug candidates are in phase III clinical trials for psoriatic arthritis treatment. These are likely to be commercialized in first half of the forecast period.
The global psoriatic arthritis therapeutics market is driven by high prevalence and increase in incidence rate of psoriatic arthritis. Patients with skin condition psoriasis have a high risk of developing psoriatic arthritis, and the number of patients has steadily increased in the last few years. People are living stressful lives, which results in overstimulation of immunity of the human body. This increases the number of patients with psoriasis, primarily the geriatric population. In the U.S., around 7.5 million people are affected with psoriasis, and around 30% of them are affected with psoriatic arthritis. Therefore, high prevalence and increase in the incidence rate of psoriasis and psoriasis led arthritis across the globe are driving the global psoriatic arthritis therapeutics market demand.
For the treatment of psoriatic arthritis, a large number of small molecules and biologic products are in various stages of clinical trials. Leading companies have made significant investment in clinical R&D and have formed strategic partnerships and collaborations to accelerate the development of new products. Interleukin inhibitors have been shown to be an effective and well-tolerated treatment for psoriatic arthritis, and three different interleukin inhibitors have recently been approved and commercialized in the U.S. and Europe. New therapeutic drug classes, such as Bristol Mayer Squibb’s TYK2 kinase inhibitor-BMS-986165, and AbbVie’s JAK inhibitor- Upadacitinib (ABT-494), are currently in phase III clinical trials for psoriatic arthritis. Hence, approval and commercialization of novel therapeutic drugs under clinical trial studies is projected to propel the global market during the forecast period.
In terms of drug class, the TNF inhibitors segment accounted for the largest share of the global market in 2021. Higher efficacy rate than small molecules, fewer alternative therapeutic drugs, and high cost are expected to drive the TNF inhibitors segment during the forecast period. Furthermore, the segment is expected to be propelled by increase in the rate of adoption of biosimilar drugs in developed countries and rise in demand in emerging markets during the forecast period.
Based on route of administration, the global market has been classified into oral, parenteral, and topical. The parenteral segment held major share of the global market in 2021. High cost and high volume prescription of biologic drugs, which are administered via intravenous and subcutaneous injections, are ascribed to the segment's large market share.
In terms of distribution channel, the hospital pharmacies segment dominated the global market in 2021. This is ascribed to increase in the number of hospital admissions for psoriatic arthritis and high treatment cost. Pipeline biologic products of leading biopharmaceutical companies are likely to receive approval and commercialization in the near future. Biologic drugs are commonly and easily available at hospital pharmacy stores. Therefore, expected launch and commercialization of biologic therapeutic drugs for psoriatic arthritis are likely to augment the hospital pharmacies segment during the forecast period.
As per global psoriatic arthritis therapeutics market forecast, North America is expected to be a highly lucrative market for psoriatic arthritis therapeutics during the forecast period. High prevalence of psoriatic arthritis, increase in adoption of biologic drugs for the treatment of moderate to severe psoriatic arthritis, and anticipated new product approvals are likely to fuel the market in North America.
The market in Asia Pacific is projected to grow at a high CAGR during the forecast period. Increase in awareness about psoriatic arthritis, rapidly changing health care infrastructure, rise in access to psoriatic arthritis pharmacotherapy and arthropathic psoriasis therapy in developing countries such as China and India, well-established pharmaceutical market in Japan, and surge in adoption of biologic drugs in Australia and New Zealand are anticipated to fuel the market in Asia Pacific during the forecast period.
Large base of biopharmaceutical companies, new product development and commercialization, increase in the adoption of biologic products, and high per capita health care expenditure in Germany and France are likely to bolster the psoriatic arthritis therapeutics market in Europe from 2022 to 2031.
Rise in purchasing power of the middle class patient population, increase in the incidence of psoriatic arthritis, and surge in launch of new biosimilars & biologic drugs are expected to propel the market in Latin America during the forecast period.
The global market is fragmented, with the presence of a large number of leading players. Key players operating in the global medical education market are AbbVie, Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, and UCB S.A. These players are adopting growth strategies such as new product development, product launches, product approval, agreement, partnerships, and merger.
Key players have been profiled in the psoriatic arthritis therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 10.8 Bn |
|
Market Forecast Value in 2031 |
More than US$ 24.2 Bn |
|
Growth Rate |
8.0% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
Market share analysis by company (2021) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials. |
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 10.8 Bn in 2021.
The global market is projected to reach more than US$ 24.2 Bn by 2031.
The global market advanced at a CAGR of 15.7% from 2017 to 2021.
The global market is anticipated to rise at a CAGR of 8.0% from 2022 to 2031.
Increase in demand for biologics, new product approvals, and high prevalence & increase in incidence rate of psoriatic arthritis.
North America is expected to account for the largest share of the global market during the forecast period.
AbbVie, Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, and UCB S.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. Covid-19 Impact Analysis
6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. TNF Inhibitors
6.3.2. Interleukin Inhibitors
6.3.3. PDE4 Inhibitors
6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. TNF Inhibitors
10.2.2. Interleukin Inhibitors
10.2.3. PDE4 Inhibitors
10.2.4. Others
10.3. Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. TNF Inhibitors
11.2.2. Interleukin Inhibitors
11.2.3. PDE4 Inhibitors
11.2.4. Others
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. TNF Inhibitors
12.2.2. Interleukin Inhibitors
12.2.3. PDE4 Inhibitors
12.2.4. Others
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. TNF Inhibitors
13.2.2. Interleukin Inhibitors
13.2.3. PDE4 Inhibitors
13.2.4. Others
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. TNF Inhibitors
14.2.2. Interleukin Inhibitors
14.2.3. PDE4 Inhibitors
14.2.4. Others
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Janssen Pharmaceutical NV
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Amgen, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Celgene Corporation
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eli Lilly and Company
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. UCB S.A
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bristol Myers Squibb
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Other Prominent Players
List of Tables
Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Psoriatic Arthritis Therapeutics Market Snapshot
Figure 02: Global Psoriatic Arthritis Therapeutics Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
Figure 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 05: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2021)
Figure 06: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2021)
Figure 04: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2021)
Figure 07: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2021)
Figure 08: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 09: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 10: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2021–2031
Figure 11: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2021–2031
Figure 12: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2021–2031
Figure 13: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021–2031
Figure 14: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 15: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 16: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2021–2031
Figure 17: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2021–2031
Figure 18: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2021–2031
Figure 19: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2031
Figure 20: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2021-2031
Figure 21: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2021–2031
Figure 22: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2021–2031
Figure 23: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021-2031
Figure 24: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
Figure 25: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 26: North America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031
Figure 27: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2031
Figure 28: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 29: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
Figure 30: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 31: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 32: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 33: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 34: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Europe Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031
Figure 36: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 37: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 38: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
Figure 39: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 40: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 41: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 42: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 43: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 44: Asia Pacific Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031
Figure 45: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 46: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 47: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
Figure 48: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 49: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 50: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 51: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 52: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 53: Latin America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031
Figure 54: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 55: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 56: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
Figure 57: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 58: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 59: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 60: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 61: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 62: Middle East & Africa Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031
Figure 63: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 64: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 65: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
Figure 66: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by drug Class, 2022–2031
Figure 67: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 68: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 69: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 70: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 71: Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2021)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Psoriatic Arthritis Therapeutics Market
